Frontlight ResearchEarly access
CompletedPhase 2
Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
Key facts
- Who runs it
- Definium Therapeutics US, Inc.
- Where
- Netherlands and Switzerland2 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 53 people enrolled
- Started
- 17 Dec 2021
- Ended
- 4 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- MM120
- Placebo
- Record updated
- 27 February 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Male and female outpatients ≥ 18 and ≤ 65 years of age at Screening
- Patients with the diagnosis of Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) ADHD, as determined by clinical evaluation and confirmed by structured interview (MINI)
- Adequate organ function
- Able to understand the study procedures and understand risks associated with the study, and sign written informed consent to participate in the study
- Must be willing to refrain from more than 6 standard alcoholic drinks a week, more than 10 cigarettes a day, and more than 2 cups of coffee a day throughout the study treatment period (6 weeks) and until the last study visit is complete
Who cannot take part
- Once Informed Consent form is signed, not willing or able to stop any prescription or non-prescription ADHD medications
- Use of investigational medication/treatment in the past 30 days
- Patients with a positive urine drug screen with the exception of THC or its metabolites
- Past or present diagnosis of a primary psychotic disorder or first degree relative with a psychotic disorder
- Past or present bipolar disorder (DSM-5)
- Any lifetime history of suicide attempt
- Pregnant or nursing females
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled
The 2 groups in the trial
- Arm 1- PlaceboPlacebo, for comparison
A total of 26 patients will receive a placebo identical in appearance to the investigational medicinal product (IMP) administered orally twice weekly (e.g., Tuesday/Friday) for 6 weeks.
Treatment: Placebo
- Arm 2- MM120Treatment being tested
A total of 26 patients will receive 20 μg of MM120 administered orally twice weekly for 6 weeks.
Treatment: MM120
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Safety and Efficacy of Repeated Low Dose d-Lysergic Acid Diethylamide (LSD) D-tartrate (MM120) as Treatment for ADHD in Adults: a Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2a Proof of Concept Trial
- Publications
- Record updated
- 27 February 2026